Hiroshi Ueda

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6224698/publications.pdf

Version: 2024-02-01

244	8,502	44069	71685
papers	citations	48 h-index	76 g-index

254	254	254	5951
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nature Medicine, 2004, 10, 712-718.	30.7	480
2	A novel analgesic dipeptide from bovine brain is a possible Met-enkephalin releaser. Nature, 1979, 282, 410-412.	27.8	260
3	Molecular mechanisms of neuropathic painâ€“phenotypic switch and initiation mechanisms. , 2006, 109, 57-77.		216
4	Morphine-like analgesia by a new dipeptide, L-Tyrosyl-L-Arginine (kyotorphin) and its analogue. European Journal of Pharmacology, 1979, 55, 109-111.	3.5	171
5	Epigenetic Gene Silencing Underlies C-Fiber Dysfunctions in Neuropathic Pain. Journal of Neuroscience, 2010, 30, 4806-4814.	3.6	169
6	Absence of morphine analgesia and its underlying descending serotonergic activation in an experimental mouse model of fibromyalgia. Neuroscience Letters, 2010, 472, 184-187.	2.1	162
7	Novel Expression of Vanilloid Receptor 1 on Capsaicin-Insensitive Fibers Accounts for the Analgesic Effect of Capsaicin Cream in Neuropathic Pain. Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 940-948.	2.5	133
8	Partial loss of tolerance liability to morphine analgesia in mice lacking the nociceptin receptor gene. Neuroscience Letters, 1997, 237, 136-138.	2.1	131
9	Comparison of the analgesic effects of various opioid peptides by a newly devised intracisternal injection technique in conscious mice. European Journal of Pharmacology, 1979, 56, 265-268.	3.5	130
10	Inhibition of Paclitaxel-Induced A-Fiber Hypersensitization by Gabapentin. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 735-740.	2.5	127
11	Increased Expression of Vanilloid Receptor 1 on Myelinated Primary Afferent Neurons Contributes to the Antihyperalgesic Effect of Capsaicin Cream in Diabetic Neuropathic Pain in Mice. Journal of Pharmacology and Experimental Therapeutics, 2003, 306, 709-717.	2.5	119
12	Low doses of naloxone produce analgesia in the mouse brain by blocking presynaptic autoinhibition of enkephalin release. Neuroscience Letters, 1986, 65, 247-252.	2.1	116
13	Enhanced Spinal Nociceptin Receptor Expression Develops Morphine Tolerance and Dependence. Journal of Neuroscience, 2000, 20, 7640-7647.	3.6	113
14	Peripheral Mechanisms of Neuropathic Pain â€" Involvement of Lysophosphatidic Acid Receptor-Mediated Demyelination. Molecular Pain, 2008, 4, 1744-8069-4-11.	2.1	112
15	Differential involvement of Î¼-opioid receptor subtypes in endomorphin-1- and -2-induced antinociception. European Journal of Pharmacology, 1999, 372, 25-30.	3.5	111
16	Loss of Peripheral Morphine Analgesia Contributes to the Reduced Effectiveness of Systemic Morphine in Neuropathic Pain. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 380-387.	2.5	109
17	Locus-Specific Rescue of GluRÏµ1 NMDA Receptors in Mutant Mice Identifies the Brain Regions Important for Morphine Tolerance and Dependence. Journal of Neuroscience, 2003, 23, 6529-6536.	3.6	108
18	Mechanisms underlying morphine analgesic tolerance and dependence. Frontiers in Bioscience - Landmark, 2009, 14, 5260.	3.0	102

#	Article	IF	Citations
19	Aripiprazole, a novel antipsychotic drug, inhibits quinpriole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. European Journal of Pharmacology, 1997, 321, 105-111.	3.5	100
20	Autotaxin, a Synthetic Enzyme of Lysophosphatidic Acid (LPA), Mediates the Induction of Nerve-Injured Neuropathic Pain. Molecular Pain, 2008, 4, 1744-8069-4-6.	2.1	94
21	Prolonged Gabapentin Analgesia in an Experimental Mouse Model of Fibromyalgia. Molecular Pain, 2008, 4, 1744-8069-4-52.	2.1	86
22	Morphine-Induced Chemotaxis and Brain-Derived Neurotrophic Factor Expression in Microglia. Journal of Neuroscience, 2005, 25, 430-435.	3.6	83
23	Lysophosphatidic acid: Chemical signature of neuropathic pain. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2013, 1831, 61-73.	2.4	81
24	Switching of Bradykinin-Mediated Nociception Following Partial Sciatic Nerve Injury in Mice. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 1158-1164.	2.5	78
25	Regional distribution of a novel analgesic dipeptide kyotorphin (Tyr-Arg) in the rat brain and spinal cord. Brain Research, 1980, 198, 460-464.	2.2	74
26	Neuropathy-specific analgesic action of intrathecal nicotinic agonists and its spinal GABA-mediated mechanism. Brain Research, 2002, 953, 53-62.	2.2	73
27	Evidence for De Novo Synthesis of Lysophosphatidic Acid in the Spinal Cord through Phospholipase A₂ and Autotaxin in Nerve Injury-Induced Neuropathic Pain. Journal of Pharmacology and Experimental Therapeutics, 2010, 333, 540-546.	2.5	71
28	Anatomical and physiological evidence for involvement of tuberoinfundibular peptide of 39 residues in nociception. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 1651-1656.	7.1	69
29	Autotaxin and Lysophosphatidic Acid₁ receptor-Mediated Demyelination of Dorsal Root Fibers by Sciatic Nerve Injury and Intrathecal Lysophosphatidylcholine. Molecular Pain, 2010, 6, 1744-8069-6-78.	2.1	69
30	<scp>HDAC</scp> inhibitors restore <scp>C</scp>â€fibre sensitivity in experimental neuropathic pain model. British Journal of Pharmacology, 2013, 170, 991-998.	5.4	69
31	Mechanism of kyotorphin-induced release of Met-enkephalin from guinea pig striatum and spinal cord. Brain Research, 1981, 221, 161-169.	2.2	67
32	Presynaptic mediation by Î±2-, Î²1- and Î²2-adrenoceptors of endogenous noradrenaline and dopamine release from slices of rat hypothalamus. Life Sciences, 1983, 33, 371-376.	4.3	67
33	Identification of prothymosin-Î±1, the necrosisâ€“apoptosis switch molecule in cortical neuronal cultures. Journal of Cell Biology, 2007, 176, 853-862.	5.2	67
34	Necessity of Lysophosphatidic Acid Receptor 1 for Development of Arthritis. Arthritis and Rheumatism, 2013, 65, 2037-2047.	6.7	67
35	Lysophosphatidic Acid-3 Receptor-Mediated Feed-Forward Production of Lysophosphatidic Acid: an Initiator of Nerve Injury-Induced Neuropathic Pain. Molecular Pain, 2009, 5, 1744-8069-5-64.	2.1	65
36	Epigenetic regulation of BDNF expression in the primary sensory neurons after peripheral nerve injury: Implications in the development of neuropathic pain. Neuroscience, 2013, 240, 147-154.	2.3	65

#	Article	IF	Citations
37	Functional Reconstitution of Purified Giand Gowith ?-Opioid Receptors in Guinea Pig Striatal Membranes Pretreated with Micromolar Concentrations of N-Ethylmaleimide. Journal of Neurochemistry, 1990, 54, 841-848.	3.9	64
38	Protein Kinase C-Mediated Inhibition of Î¼-Opioid Receptor Internalization and Its Involvement in the Development of Acute Tolerance to Peripheral Î¼-Agonist Analgesia. Journal of Neuroscience, 2001, 21, 2967-2973.	3.6	64
39	Lysophosphatidic acidâ€induced membrane ruffling and brainâ€derived neurotrophic factor gene expression are mediated by ATP release in primary microglia. Journal of Neurochemistry, 2008, 107, 152-160.	3.9	64
40	LPA-mediated demyelination in ex vivo culture of dorsal root. Neurochemistry International, 2007, 50, 351-355.	3.8	62
41	Microglial activation mediates de novo lysophosphatidic acid production in a model of neuropathic pain. Journal of Neurochemistry, 2010, 115, 643-653.	3.9	62
42	Pain and the bulbospinal noradrenergic system: pain-induced increase in normetanephrine content in the spinal cord and its modification by morphine. European Journal of Pharmacology, 1979, 54, 99-107.	3.5	59
43	Lysophosphatidic acid-induced, pertussis toxin-sensitive nociception through a substance P release from peripheral nerve endings in mice. Neuroscience Letters, 1999, 270, 59-61.	2.1	59
44	Nociceptin-induced scratching, biting and licking in mice: involvement of spinal NK1 receptors. British Journal of Pharmacology, 1999, 127, 1712-1718.	5.4	57
45	Lysophosphatidic Acid and its Receptors LPA₁ and LPA₃ Mediate Paclitaxel-Induced Neuropathic Pain in Mice. Molecular Pain, 2014, 10, 1744-8069-10-71.	2.1	52
46	Neurotransmitter-like Actions of L-DOPA. Advances in Pharmacology, 1995, 32, 427-459.	2.0	50
47	Cell Death Mode Switch from Necrosis to Apoptosis in Brain. Biological and Pharmaceutical Bulletin, 2004, 27, 950-955.	1.4	50
48	Evidence for lysophosphatidic acid 1 receptor signaling in the early phase of neuropathic pain mechanisms in experiments using Kiâ€16425, a lysophosphatidic acid 1 receptor antagonist. Journal of Neurochemistry, 2009, 109, 603-610.	3.9	50
49	An LPA Species (18:1 LPA) Plays Key Roles in the Self-Amplification of Spinal LPA Production in the Peripheral Neuropathic Pain Model. Molecular Pain, 2013, 9, 1744-8069-9-29.	2.1	50
50	Vzg-1/lysophosphatidic acid-receptor involved in peripheral pain transmission. Molecular Brain Research, 2000, 75, 350-354.	2.3	49
51	Î´ Opioid receptor mediates phospholipase C activation via GiinXenopusoocytes. FEBS Letters, 1993, 333, 311-314.	2.8	48
52	Tonic inhibitory role of Î±4Î²2 subtype of nicotinic acetylcholine receptors on nociceptive transmission in the spinal cord in mice. Pain, 2006, 125, 125-135.	4.2	48
53	Non-effective dose of exogenously applied l-DOPA itself stereoselectively potentiates postsynaptic D2 receptor-mediated locomotor activities of conscious rats. Neuroscience Letters, 1994, 170, 22-26.	2.1	47
54	Simultaneous stimulation of spinal NK1 and NMDA receptors produces LPC which undergoes ATXâ€mediated conversion to LPA, an initiator of neuropathic pain. Journal of Neurochemistry, 2008, 107, 1556-1565.	3.9	45

#	Article	IF	Citations
55	Pharmacological Switch in AÎ²-Fiber Stimulation-Induced Spinal Transmission in Mice with Partial Sciatic Nerve Injury. Molecular Pain, 2008, 4, 1744-8069-4-25.	2.1	45
56	Retinal cell typeâ€specific prevention of ischemiaâ€induced damages by <scp>LPS</scp>â€<scp>TLR</scp>4 signaling through microglia. Journal of Neurochemistry, 2013, 126, 243-260.	3.9	44
57	Phosphorylated Î¼-opioid receptor purified from rat brains lacks functional coupling with Gi1, a GTP-binding protein in reconstituted lipid vesicles. Neuroscience Letters, 1990, 113, 47-49.	2.1	42
58	Endogenously released l-DOPA itself tonically functions to potentiate postsynaptic D2 receptor-mediated locomotor activities of conscious rats. Neuroscience Letters, 1994, 170, 107-110.	2.1	41
59	New approaches to study the development of morphine tolerance and dependence. Life Sciences, 2003, 74, 313-320.	4.3	41
60	Endocrine Disrupting Chemical Atrazine Causes Degranulation through Gq/11 Protein-Coupled Neurosteroid Receptor in Mast Cells. Toxicological Sciences, 2006, 90, 362-368.	3.1	41
61	Complete inhibition of purinoceptor agonist-induced nociception by spinorphin, but not by morphine. Peptides, 2000, 21, 1215-1221.	2.4	39
62	Neurosteroids stimulate G protein-coupled sigma receptors in mouse brain synaptic membrane. Neuroscience Research, 2001, 41, 33-40.	1.9	39
63	Curcumin blocks chronic morphine analgesic tolerance and brain-derived neurotrophic factor upregulation. NeuroReport, 2009, 20, 63-68.	1.2	39
64	Calpainâ€mediated downâ€regulation of myelinâ€associated glycoprotein in lysophosphatidic acidâ€induced neuropathic pain. Journal of Neurochemistry, 2010, 113, 1002-1011.	3.9	39
65	A rapid, comprehensive system for assaying DNA repair activity and cytotoxic effects of DNA-damaging reagents. Nature Protocols, 2015, 10, 12-24.	12.0	39
66	Loss of Spinal Substance P Pain Transmission under the Condition of LPA₁ Receptor-Mediated Neuropathic Pain. Molecular Pain, 2006, 2, 1744-8069-2-25.	2.1	38
67	Characterization of Three Different Sensory Fibers by use of Neonatal Capsaicin Treatment, Spinal Antagonism and a Novel Electrical Stimulation-Induced Paw Flexion Test. Molecular Pain, 2006, 2, 1744-8069-2-16.	2.1	38
68	Emerging functions for tuberoinfundibular peptide of 39 residues. Trends in Endocrinology and Metabolism, 2003, 14, 14-19.	7.1	37
69	Prothymosin Î± and cell death mode switch, a novel target for the prevention of cerebral ischemia-induced damage. , 2009, 123, 323-333.		37
70	Prothymosinâ€alpha preconditioning activates <scp>TLR</scp>4â€“<scp>TRIF</scp> signaling to induce protection of ischemic retina. Journal of Neurochemistry, 2015, 135, 1161-1177.	3.9	37
71	Lysophosphatidic acid signaling is the definitive mechanism underlying neuropathic pain. Pain, 2017, 158, S55-S65.	4.2	37
72	Evidence for the Tonic Inhibition of Spinal Pain by Nicotinic Cholinergic Transmission through Primary Afferents. Molecular Pain, 2007, 3, 1744-8069-3-41.	2.1	36

#	Article	IF	Citations
73	Permanent Relief from Intermittent Cold Stress-Induced Fibromyalgia-Like Abnormal Pain by Repeated Intrathecal Administration of Antidepressants. Molecular Pain, 2011, 7, 1744-8069-7-69.	2.1	36
74	Melittin, a Metabostatic Peptide Inhibiting Gs Activity. Peptides, 1998, 19, 811-819.	2.4	35
75	Phosphorylation of Î¼-opioid receptors â€" a putative mechanism of selective uncoupling of receptor â€" Gi interaction, measured with low-Km CTPase and nucleotide-sensitive agonist binding. Neuroscience Letters, 1989, 100, 221-226.	2.1	34
76	Opioid Î¼- and Î¹-receptor mediate phospholipase C activation through Gi1 in Xenopus oocytes. Molecular Brain Research, 1995, 32, 166-170.	2.3	34
77	Characterization of nociceptin-stimulated in situ [35S]GTPÎ³S binding in comparison with opioid agonist-stimulated ones in brain regions of the mice. Neuroscience Letters, 1997, 237, 113-116.	2.1	34
78	Involvement of lysophosphatidic acidâ€"induced astrocyte activation underlying the maintenance of partial sciatic nerve injuryâ€"induced neuropathic pain. Pain, 2018, 159, 2170-2178.	4.2	34
79	Analgesic dipeptide, kyotorphin (Tyr-Arg), is highly concentrated in the synaptosomal fraction of the rat brain. Brain Research, 1982, 231, 222-224.	2.2	33
80	Insulin Receptor-Protein Kinase C-Î³ Signaling Mediates Inhibition of Hypoxia-Induced Necrosis of Cortical Neurons. Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 1027-1034.	2.5	32
81	Involvement of LPA1Receptor Signaling in the Reorganization of Spinal Input through Abeta-Fibers in Mice with Partial Sciatic Nerve Injury. Molecular Pain, 2008, 4, 1744-8069-4-46.	2.1	32
82	Antinociceptive Effect of Cyclic Phosphatidic Acid and Its Derivative on Animal Models of Acute and Chronic Pain. Molecular Pain, 2011, 7, 1744-8069-7-33.	2.1	32
83	l-DOPA inhibits spontaneous acetylcholine release from the striatum of experimental Parkinson's model rats. Brain Research, 1995, 698, 213-216.	2.2	31
84	Î¹-Opioid agonist inhibits phospholipase C, possibly via an inhibition of G-protein activity. Neuroscience Letters, 1990, 112, 324-327.	2.1	30
85	Inositol 1,4,5-Trisphosphate-Gated Calcium Transport through Plasma Membranes in Nerve Terminals. Journal of Neuroscience, 1996, 16, 2891-2900.	3.6	30
86	Nonopioid and Neuropathy-Specific Analgesic Action of the Nootropic Drug Nefiracetam in Mice. Journal of Pharmacology and Experimental Therapeutics, 2002, 303, 226-231.	2.5	30
87	Lysophosphatidic Acid as the Initiator of Neuropathic Pain. Biological and Pharmaceutical Bulletin, 2011, 34, 1154-1158.	1.4	30
88	Lysophosphatidic acid LPA1 and LPA3 receptors play roles in the maintenance of late tissue plasminogen activator-induced central poststroke pain in mice. Neurobiology of Pain (Cambridge, Mass), 2019, 5, 100020.	2.5	30
89	The effect of polysorbate 80 on brain uptake and analgesic effect of D-kyotorphin. International Journal of Pharmaceutics, 1989, 57, 77-83.	5.2	29
90	Cell density-dependent death mode switch of cultured cortical neurons under serum-free starvation stress. Cellular and Molecular Neurobiology, 2001, 21, 317-324.	3.3	29

#	Article	IF	Citations
91	Downregulation of P2X3receptor-dependent sensory functions in A/J inbred mouse strain. European Journal of Neuroscience, 2002, 15, 1444-1450.	2.6	29
92	In Vivo Pain-Inhibitory Role of Nociceptin/Orphanin FQ in Spinal Cord. Journal of Pharmacology and Experimental Therapeutics, 2003, 305, 495-501.	2.5	29
93	Locusâ€Specific Involvement of Antiâ€Opioid Systems in Morphine Tolerance and Dependence. Annals of the New York Academy of Sciences, 2004, 1025, 376-382.	3.8	29
94	Profiling of BoNT/C3-reversible gene expression induced by lysophosphatidic acid: ephrinB1 gene up-regulation underlying neuropathic hyperalgesia and allodynia. Neurochemistry International, 2009, 54, 215-221.	3.8	29
95	Molecular mechanism of neuropathic pain. Drug News and Perspectives, 2003, 16, 605.	1.5	29
96	Evidence for serum-deprivation-induced co-release of FGF-1 and S100A13 from astrocytes. Neurochemistry International, 2006, 49, 294-303.	3.8	28
97	Evidence for receptor-mediated inhibition of intrinsic activity of GTP-binding protein, Gi1 and Gi2, but not G0in reconstitution experiments. FEBS Letters, 1990, 266, 178-182.	2.8	27
98	Stable G protein-effector complexes in striatal neurons: mechanism of assembly and role in neurotransmitter signaling. ELife, 2015, 4, .	6.0	27
99	Histone deacetylase inhibitors relieve morphine resistance in neuropathic pain after peripheral nerve injury. Journal of Pharmacological Sciences, 2015, 128, 208-211.	2.5	27
100	LPA1 receptor involvement in fibromyalgia-like pain induced by intermittent psychological stress, empathy. Neurobiology of Pain (Cambridge, Mass), 2017, 1, 16-25.	2.5	27
101	A putative met-enkephalin releaser, kyotorphin enhances intracellular Ca2+ in the synaptosomes. Biochemical and Biophysical Research Communications, 1986, 137, 897-902.	2.1	26
102	Purified opioid Î¼-receptor is of a different molecular size than Î´- and Îº-receptors. Neuroscience Letters, 1987, 75, 339-344.	2.1	26
103	Novel type of Gq/11 protein-coupled neurosteroid receptor sensitive to endocrine disrupting chemicals in mast cell line (RBL-2H3). British Journal of Pharmacology, 2005, 145, 545-550.	5.4	26
104	The specific opioid Îº-agonist U-50,488H inhibits low Km GTPase. European Journal of Pharmacology, 1987, 138, 129-132.	3.5	25
105	Peripheral non-opioid analgesic effects of kyotorphin in mice. Neuroscience Letters, 1997, 236, 60-62.	2.1	25
106	Prothymosin Î± plays multifunctional cell robustness roles in genomic, epigenetic, and nongenomic mechanisms. Annals of the New York Academy of Sciences, 2012, 1269, 34-43.	3.8	25
107	Minocycline Does Not Decrease Intensity of Neuropathic Pain, but Improves Its Affective Dimension. Journal of Pain and Palliative Care Pharmacotherapy, 2016, 30, 1-6.	0.8	25
108	Epigenetic Modification in Neuropathic Pain. Current Pharmaceutical Design, 2014, 21, 849-867.	1.9	25

#	Article	IF	Citations
109	Presynaptic Î±2- and dopamine-receptor-mediated inhibitory mechanisms and dopamine nerve terminals in the rat hypothalamus. Neuroscience Letters, 1983, 40, 157-162.	2.1	24
110	Sigma ligands stimulate GTPase activity in mouse prefrontal membranes: evidence for the existence of metabotropic sigma receptor. Neuroscience Letters, 1997, 233, 141-144.	2.1	24
111	Activation of Gi1by Lysophosphatidic Acid Receptor without Ligand in the Baculovirus Expression System. Biochemical and Biophysical Research Communications, 1999, 259, 78-84.	2.1	24
112	Serum-free induced neuronal apoptosis-like cell death is independent of caspase activity. Molecular Brain Research, 2000, 78, 186-191.	2.3	24
113	Microglia Activation Precedes the Anti-Opioid BDNF and NMDA Receptor Mechanisms Underlying Morphine Analgesic Tolerance. Current Pharmaceutical Design, 2014, 19, 7355-7361.	1.9	24
114	Pertussis toxin (IAP) enhances maitotoxin (a putative Ca2+ channel agonist)-induced Ca2+ entry into synaptosomes. European Journal of Pharmacology, 1986, 122, 379-380.	3.5	23
115	Supersensitization of intrastriatal dopamine receptors involved in opposite regulation of acetylcholine release in Parkinson's model rats. Neuroscience Letters, 1994, 173, 59-62.	2.1	23
116	Neuronal Necrosis Inhibition by Insulin through Protein Kinase C Activation. Journal of Pharmacology and Experimental Therapeutics, 2003, 307, 205-212.	2.5	23
117	Interleukin-1Î² Plays Key Roles in LPA-Induced Amplification of LPA Production in Neuropathic Pain Model. Cellular and Molecular Neurobiology, 2013, 33, 1033-1041.	3.3	23
118	NMDA receptor agonists reverse impaired psychomotor and cognitive functions associated with hippocampal Hbegf-deficiency in mice. Molecular Brain, 2015, 8, 83.	2.6	22
119	Excess release of substance P from the spinal cord of mice during morphine withdrawal and involvement of the enhancement of presynaptic Ca2+ entry. Brain Research, 1987, 425, 101-105.	2.2	21
120	Novel neuroprotective action of prothymosin alphaâ€derived peptide against retinal and brain ischemic damages. Journal of Neurochemistry, 2013, 125, 713-723.	3.9	21
121	A mimetic of the mSin3-binding helix of NRSF/REST ameliorates abnormal pain behavior in chronic pain models. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4705-4709.	2.2	21
122	LPA5 signaling is involved in multiple sclerosis-mediated neuropathic pain in the cuprizone mouse model. Journal of Pharmacological Sciences, 2018, 136, 93-96.	2.5	21
123	Pathogenic mechanisms of lipid mediator lysophosphatidic acid in chronic pain. Progress in Lipid Research, 2021, 81, 101079.	11.6	21
124	Presynaptic opioid Îº-receptor and regulation of the release of Met-enkephalin in the rat brainstem. Neuroscience Letters, 1987, 81, 309-313.	2.1	20
125	Peripheral morphine analgesia resistant to tolerance in chronic morphine-treated mice. Neuroscience Letters, 1999, 266, 105-108.	2.1	20
126	Stimulation of peripheral nociceptor endings by low dose morphine and its signaling mechanism. Neurochemistry International, 2002, 41, 399-407.	3.8	20

#	Article	IF	Citations
127	NSAID zaltoprofen possesses novel anti-nociceptive mechanism through blockage of B2-type bradykinin receptor in nerve endings. Neuroscience Letters, 2006, 397, 249-253.	2.1	20
128	Circadian-Dependent Learning and Memory Enhancement in Nociceptin Receptor-Deficient Mice with a Novel KUROBOX Apparatus Using Stress-Free Positive Cue Task. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 195-201.	2.5	20
129	Uptake and release of kyotorphin in rat brain synaptosomes. Life Sciences, 1986, 38, 2405-2411.	4.3	19
130	Protein kinase inhibitor potentiates opioid Î´-receptor currents in Xenopus oocytes. NeuroReport, 1994, 5, 1985-1988.	1.2	19
131	Single Application of A2 NTX, a Botulinum Toxin A2 Subunit, Prevents Chronic Pain Over Long Periods in Both Diabetic and Spinal Cord Injury^|^ndash;Induced Neuropathic Pain Models. Journal of Pharmacological Sciences, 2012, 119, 282-286.	2.5	19
132	Critical Functionality Effects from Storage Temperature on Human Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium Cell Suspensions. Scientific Reports, 2019, 9, 2891.	3.3	19
133	LPA receptor signaling as a therapeutic target for radical treatment of neuropathic pain and fibromyalgia. Pain Management, 2020, 10, 43-53.	1.5	19
134	Studies on peptides. XCIV. Synthesis and activity of kyotorphin and its analogs.. Chemical and Pharmaceutical Bulletin, 1980, 28, 1935-1938.	1.3	18
135	The maitotoxin-evoked Ca2+ entry into synaptosomes is enhanced by cholera toxin. Neuroscience Letters, 1986, 67, 141-146.	2.1	18
136	A subtype of opioid Î¹-receptor is coupled to inhibition of Gil-mediated phospholipase C activity in the guinea pig cerebellum. FEBS Letters, 1995, 361, 106-110.	2.8	18
137	Low-density induced apoptosis of cortical neurons is inhibited by serum factors. Cellular and Molecular Neurobiology, 1998, 18, 487-496.	3.3	18
138	Selective coupling of mouse brain metabotropic sigma (Ïƒ) receptor with recombinant Gi1. Neuroscience Letters, 1999, 268, 85-88.	2.1	18
139	Neuroprotective DAMPs member prothymosin alpha has additional beneficial actions against cerebral ischemia-induced vascular damages. Journal of Pharmacological Sciences, 2016, 132, 100-104.	2.5	18
140	Adrenaline involvement in the presynaptic Î²-adrenoceptor-mediated mechanism of dopamine release from slices of the rat hypothalamus. Life Sciences, 1984, 34, 1087-1093.	4.3	17
141	Non-opioid analgesia of the neuropeptide, neo-kyotorphin and possible mediation by inhibition of GABA release in the mouse brain. Peptides, 1987, 8, 905-909.	2.4	17
142	(-)1-(Benzofuran-2-yl)-2-propylaminopentane shows survival effect on cortical neurons under serum-free condition through sigma receptors. Cellular and Molecular Neurobiology, 2000, 20, 695-702.	3.3	17
143	The algogenic-induced nociceptive flexion test in mice: studies on sensitivity of the test and stress on animals. Brain Research Bulletin, 2003, 60, 275-281.	3.0	17
144	Nocistatin and Prepro-Nociceptin/Orphanin FQ 160â€“187 Cause Nociception through Activation of Gi/oin Capsaicin-Sensitive and of Gsin Capsaicin-Insensitive Nociceptors, Respectively. Journal of Pharmacology and Experimental Therapeutics, 2003, 306, 141-146.	2.5	17

#	Article	IF	Citations
145	Voltage-Dependent N-Type Ca2+ Channel Activity Regulates the Interaction Between FGF-1 and S100A13 for Stress-Induced Non-Vesicular Release. Cellular and Molecular Neurobiology, 2006, 26, 237-246.	3.3	17
146	Lys39-Lysophosphatidate Carbonyl Oxygen Interaction Locks LPA1 N-terminal Cap to the Orthosteric Site and partners Arg124 During Receptor Activation. Scientific Reports, 2015, 5, 13343.	3.3	17
147	Myelin-related gene silencing mediated by LPA1 â€“ Rho/ROCK signaling is correlated to acetylation of NFÎºB in S16 Schwann cells. Journal of Pharmacological Sciences, 2016, 132, 162-165.	2.5	17
148	Species and age-dependent differences of functional coupling between opioid Î´-receptor and G-proteins and possible involvement of protein kinase C in striatal membranes. Neuroscience Letters, 1994, 176, 55-58.	2.1	16
149	Neurosteroid-induced hyperalgesia through a histamine release is inhibited by progesterone and p,pâ€²-DDE, an endocrine disrupting chemical. Neurochemistry International, 2003, 42, 401-407.	3.8	16
150	Prothymosin Î± plays a key role in cell death mode-switch, a new concept for neuroprotective mechanisms in stroke. Naunyn-Schmiedeberg's Archives of Pharmacology, 2008, 377, 315-323.	3.0	16
151	Neuronâ€specific nonâ€classical release of prothymosin alpha: a novel neuroprotective damageâ€associated molecular patterns. Journal of Neurochemistry, 2012, 123, 262-275.	3.9	16
152	Ageâ€dependent dystonia in striatal GÎ³7 deficient mice is reversed by the dopamine D2 receptor agonist pramipexole. Journal of Neurochemistry, 2013, 124, 844-854.	3.9	16
153	Donepezil Reverses Intermittent Stress-Induced Generalized Chronic Pain Syndrome in Mice. Journal of Pharmacology and Experimental Therapeutics, 2015, 353, 471-479.	2.5	16
154	Association Between Polymorphisms in the Purinergic P2Y12 Receptor Gene and Severity of Both Cancer Pain and Postoperative Pain. Pain Medicine, 2018, 19, 348-354.	1.9	16
155	In vivo signal transduction of tetrodotoxin-sensitive nociceptive responses by substance P given into the planta of the mouse hind limb. Cellular and Molecular Neurobiology, 1998, 18, 555-561.	3.3	15
156	Prothymosin Î± as robustness molecule against ischemic stress to brain and retina. Annals of the New York Academy of Sciences, 2010, 1194, 20-26.	3.8	15
157	Molecular dynamics study-based mechanism of nefiracetam-induced NMDA receptor potentiation. Computational Biology and Chemistry, 2015, 55, 14-22.	2.3	15
158	Prothymosin alphaâ€deficiency enhances anxietyâ€like behaviors and impairs learning/memory functions and neurogenesis. Journal of Neurochemistry, 2017, 141, 124-136.	3.9	15
159	A novel method for the synthesis of kyotorphin, Tyr-Arg, and 3H-Tyr-Arg, catalyzed by tyrosyl-tRNA synthetase from Bacillus stearothermophilus. Pharmaceutical Research, 1987, 04, 154-157.	3.5	14
160	Calcium-activated neutral protease (CANP), a putative processing enzyme of the neuropeptide, kyotorphin, in the brain. Biochemical and Biophysical Research Communications, 1988, 155, 546-553.	2.1	14
161	Binding of [35S]GTPÎ³S stimulated by (+)-pentazocine, sigma receptor agonist, is abundant in the guinea pig spleen. Life Sciences, 2000, 67, 599-603.	4.3	14
162	Morphine-induced overexpression of prepro-nociceptin/orphanin FQ in cultured astrocytes. Peptides, 2005, 26, 2513-2517.	2.4	14

#	Article	IF	Citations
163	Synergistic Ca2+ and Cu2+ requirements of the FGF1â€“S100A13 interaction measured by quartz crystal microbalance: An initial step in amlexanox-reversible non-classical release of FGF1. Neurochemistry International, 2008, 52, 1076-1085.	3.8	14
164	Parathyroid hormone 2 receptor is a functional marker of nociceptive myelinated fibers responsible for neuropathic pain. Journal of Neurochemistry, 2010, 112, 521-530.	3.9	14
165	P-glycoprotein inhibitors improve effective dose and time of pregabalin to inhibit intermittent cold stress-induced central pain. Journal of Pharmacological Sciences, 2016, 131, 64-67.	2.5	14
166	Neuroprotective impact of prothymosin alpha-derived hexapeptide against retinal ischemiaâ€“reperfusion. Neuroscience, 2016, 318, 206-218.	2.3	14
167	Amlexanox Inhibits Cerebral Ischemia-Induced Delayed Astrocytic High-Mobility Group Box 1 Release and Subsequent Brain Damage. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 27-36.	2.5	14
168	Subconvulsive doses of intracisternal bicuculline methiodide, a GABAA receptor antagonist, produce potent analgesia as measured in the tail pinch test in mice. European Journal of Pharmacology, 1987, 136, 129-131.	3.5	13
169	Parallel Stimulations of in Vitro and in Situ [35S]GTPÎ³S Binding by Endomorphin 1 and DAMGO in Mouse Brains. Peptides, 1998, 19, 755-758.	2.4	13
170	Neurobiology of the Edg2 Lysophosphatidic Acid Receptor. The Japanese Journal of Pharmacology, 2001, 87, 104-109.	1.2	13
171	Preâ€emptive morphine treatment abolishes nerve injuryâ€induced lysophospholipid synthesis in mass spectrometrical analysis. Journal of Neurochemistry, 2011, 118, 256-265.	3.9	13
172	Prothymosin alpha and its mimetic hexapeptide improve delayed tissue plasminogen activatorâ€induced brain damage following cerebral ischemia. Journal of Neurochemistry, 2020, 153, 772-789.	3.9	13
173	Botulinum Toxin C3 Inhibits Hyperalgesia in Mice With Partial Sciatic Nerve Injury.. The Japanese Journal of Pharmacology, 2000, 83, 161-163.	1.2	12
174	Gi1and GoAdifferentially determine kinetic efficacies of agonists for Îº-opioid receptor. FEBS Letters, 2000, 473, 101-105.	2.8	12
175	The Cognition-Enhancer Nefiracetam Inhibits Both Necrosis and Apoptosis in Retinal Ischemic Models in Vitro and in Vivo. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 200-207.	2.5	12
176	Endocrine disrupting chemicals bind to a novel receptor, microtubuleâ€associated protein 2, and positively and negatively regulate dendritic outgrowth in hippocampal neurons. Journal of Neurochemistry, 2010, 114, 1333-1343.	3.9	12
177	Lysophosphatidic acid as an initiator of neuropathic pain: biosynthesis and demyelination. Clinical Lipidology, 2011, 6, 147-158.	0.4	12
178	Evidence for ProTÎ±-TLR4/MD-2 binding: molecular dynamics and gravimetric assay studies. Expert Opinion on Biological Therapy, 2015, 15, 223-229.	3.1	12
179	Subcellular dissemination of prothymosin alpha at normal physiology: immunohistochemical vis-a-vis western blotting perspective. BMC Physiology, 2016, 16, 2.	3.6	12
180	NR2A-NMDA Receptor Blockade Reverses the Lack of Morphine Analgesia Without Affecting Chronic Pain Status in a Fibromyalgia-Like Mouse Model. Journal of Pharmacology and Experimental Therapeutics, 2020, 373, 103-112.	2.5	12

#	Article	IF	Citations
181	Supersensitivity of quinpirole-evoked GTPase activation without changes in gene expression of D2 and Gi protein in the striatum of hemi-dopaminergic lesioned rats. Neuroscience Letters, 1994, 175, 107-110.	2.1	11
182	Abrogation of lysophosphatidic acid receptor 1 ameliorates murine vasculitis. Arthritis Research and Therapy, 2019, 21, 191.	3.5	11
183	Signaling of lysophosphatidic acid-evoked chloride current: calcium release from inositol trisphosphate-sensitive store. Molecular Brain Research, 1998, 61, 232-237.	2.3	10
184	Systems Pathology of Neuropathic Pain and Fibromyalgia. Biological and Pharmaceutical Bulletin, 2019, 42, 1773-1782.	1.4	10
185	Diminished Î±2-adrenoceptor-mediated modulation of noradrenergic neurotransmission in the posterior hypothalamus of spontaneously hypertensive rats. Neuroscience Letters, 1986, 65, 29-34.	2.1	9
186	Endogenous GABA released into the fourth ventricle of the rat brain in vivo is enhanced by noxious stimuli. Neuroscience Letters, 1988, 92, 76-81.	2.1	9
187	Evidence for a metabostatic opioid Ï°-receptor inhibiting pertussis toxin-sensitive metabotropic glutamate receptor-currents inXenopusoocytes. FEBS Letters, 1995, 375, 201-205.	2.8	9
188	An enzymatically stable kyotorphin analog induces pain in subattomol dosesâ˜†. Peptides, 2000, 21, 717-722.	2.4	9
189	The cognition-enhancer nefiracetam is protective in BDNF-independent neuronal cell death under the serum-free condition. Neurochemistry International, 2002, 40, 139-143.	3.8	9
190	A Subtype of Î²-Opioid Receptor Mediates Inhibition of High-Affinity GTPase Inherent in Gi1 in Guinea Pig Cerebellar Membranes. Journal of Neurochemistry, 2002, 66, 845-851.	3.9	9
191	Therapeutic benefits of 9-amino acid peptide derived from prothymosin alpha against ischemic damages. Peptides, 2013, 43, 68-75.	2.4	9
192	Low dose of kyotorphin (tyrosineâ€“arginine) induces nociceptive responses through a substance P release from nociceptor endings. Molecular Brain Research, 1999, 69, 302-305.	2.3	8
193	Pre-Injury Administration of Morphine Prevents Development of Neuropathic Hyperalgesia through Activation of Descending Monoaminergic Mechanisms in the Spinal Cord in Mice. Molecular Pain, 2005, 1, 1744-8069-1-19.	2.1	8
194	Anti-Opioid Systems in Morphine Tolerance and Addiction-Locus-Specific Involvement of Nociceptin and the NMDA Receptor. Novartis Foundation Symposium, 2008, , 155-166.	1.1	8
195	Regional Distribution and Cell Type-Specific Subcellular Localization of Prothymosin Alpha in Brain. Cellular and Molecular Neurobiology, 2012, 32, 59-66.	3.3	8
196	Tyrosyl-tRNA synthetase: A potential kyotorphin synthetase in mammals. Peptides, 2018, 101, 60-68.	2.4	8
197	Lysophosphatidic Acid Receptor 1- and 3-Mediated Hyperalgesia and Hypoalgesia in Diabetic Neuropathic Pain Models in Mice. Cells, 2020, 9, 1906.	4.1	8
198	Down-regulation of AMPA-type glutamate receptor gene expression during goldfish optic nerve regeneration. Molecular Brain Research, 1995, 32, 151-155.	2.3	7

#	Article	IF	Citations
199	Ecto-F₀/F₁ ATPase as a novel candidate of prothymosin Î± receptor. Expert Opinion on Biological Therapy, 2018, 18, 89-94.	3.1	7
200	Secreted PLA2-III is a possible therapeutic target to treat neuropathic pain. Biochemical and Biophysical Research Communications, 2021, 568, 167-173.	2.1	7
201	Chronic generalized pain disrupts whole brain functional connectivity in mice. Brain Imaging and Behavior, 2021, 15, 2406-2416.	2.1	7
202	A Met-enkephalin releaser (kyotorphin)-induced release of plasma membrane-bound Ca2+ from rat brain synaptosomes. Brain Research, 1987, 419, 197-200.	2.2	6
203	Multiple Forms of AMPA-Type Glutamate Receptor mRNA Phenotypes in Goldfish Retina and Tectum. General Pharmacology, 1997, 29, 575-581.	0.7	6
204	Kyotorphin has a novel action on rat cardiac muscle. Biochemical and Biophysical Research Communications, 2006, 339, 805-809.	2.1	6
205	High-Throughput Screening and Prediction Model Building for Novel Hemozoin Inhibitors Using Physicochemical Properties. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	6
206	Experimental evidence for the involvement of F0/F1 ATPase and subsequent P2Y12 receptor activation in prothymosin alpha-induced protection of retinal ischemic damage. Journal of Pharmacological Sciences, 2020, 143, 127-131.	2.5	6
207	Review of Kyotorphin Research: A Mysterious Opioid Analgesic Dipeptide and Its Molecular, Physiological, and Pharmacological Characteristics. Frontiers in Medical Technology, 2021, 3, 662697.	2.5	6
208	A novel proenkephalin processing carboxypeptidase and its activation by cyclic AMP dependent protein kinase. Biochemical and Biophysical Research Communications, 1987, 142, 595-602.	2.1	5
209	Mirtazapine, an Î±2 Antagonist-Type Antidepressant, Reverses Pain and Lack of Morphine Analgesia in Fibromyalgia-Like Mouse Models. Journal of Pharmacology and Experimental Therapeutics, 2020, 375, 1-9.	2.5	5
210	Allodynia by Splenocytes From Mice With Acid-Induced Fibromyalgia-Like Generalized Pain and Its Sexual Dimorphic Regulation by Brain Microglia. Frontiers in Neuroscience, 2020, 14, 600166.	2.8	5
211	Beneficial actions of prothymosin alpha-mimetic hexapeptide on central post-stroke pain, reduced social activity, learning-deficit and depression following cerebral ischemia in mice. Peptides, 2020, 126, 170265.	2.4	5
212	Effects of yohimbine on endogenous noradrenaline release from hypothalamus and brainstem slices of spontaneously hypertensive rats.. The Japanese Journal of Pharmacology, 1984, 36, 416-418.	1.2	4
213	Protein kinase C inhibitor potentiates the agonist-induced GTPase activity in COS cell membranes expressing Î´-opioid receptor. Molecular Brain Research, 1995, 33, 347-350.	2.3	4
214	Enhanced nociception by exogenous and endogenous substance P given into the spinal cord in mice lacking NR2 A/Îµ1 , an NMDA receptor subunit. British Journal of Pharmacology, 2000, 129, 239-241.	5.4	4
215	Annexin A2 Flop-Out Mediates the Non-Vesicular Release of DAMPs/Alarmins from C6 Glioma Cells Induced by Serum-Free Conditions. Cells, 2021, 10, 567.	4.1	4
216	Involvement of GABA in the analgesic mechanisms of opioids and neo-kyotorphin (non-opioid analgesic) Tj ETQq0 0 0 rgBT /Overlock 10	1.2	3

#	Article	IF	Citations
217	Involvement of kyotorphin and kyotorphin synthetase in the pain modulation. The Japanese Journal of Pharmacology, 1988, 46, 248.	1.2	3
218	ALTERED BASAL RELEASE AND DEPRESSOR EFFECT OF L-DOPA IN THE NUCLEUS TRACTUS SOLITARII OF SPONTANEOUSLY HYPERTENSIVE RATS. Clinical and Experimental Pharmacology and Physiology, 1995, 22, S34-S36.	1.9	3
219	Is BoNT/B useful for pain treatment?. Pain, 2014, 155, 649-650.	4.2	3
220	Blockade of analgesic effects following systemic administration of N-methyl-kyotorphin, NMYR and arginine in mice deficient of preproenkephalin or proopiomelanocortin gene. Peptides, 2018, 107, 10-16.	2.4	3
221	Gî³7-specific prothymosin alpha deletion causes stress- and age-dependent motor dysfunction and anxiety. Biochemical and Biophysical Research Communications, 2020, 522, 264-269.	2.1	3
222	A Novel Unified Ab Initio and Template-Based Approach to GPCR Modeling: Case of EDG-LPA Receptors.. Current Bioinformatics, 2013, 8, 603-610.	1.5	3
223	Identification and characterization of kyotorphin synthetase. The Japanese Journal of Pharmacology, 1986, 40, 219.	1.2	2
224	ALTERED BASAL RELEASE AND PRESSOR EFFECT OF L-DOPA IN THE ROSTRAL VENTROLATERAL MEDULLA OF SPONTANEOUSLY HYPERTENSIVE RATS. Clinical and Experimental Pharmacology and Physiology, 1995, 22, S43-S45.	1.9	2
225	Antiamnesic action of cromakalim, a potassium channel opener, in mice treated with hypoxia- and cerebral ischemia-type stress stimuli. Cellular and Molecular Neurobiology, 1998, 18, 429-436.	3.3	2
226	Attempts to Classify Dependence-Liable Drugs by Using a Simple Drug-Discrimination Test in Mice. General Pharmacology, 1998, 30, 697-700.	0.7	2
227	Summary of the Fibromyalgia Research Symposium 2016 in Nagasaki. Pain Reports, 2017, 2, e582.	2.7	2
228	Involvement of SNARE Protein Interaction for Non-classical Release of DAMPs/Alarmins Proteins, Prothymosin Alpha and S100A13. Cellular and Molecular Neurobiology, 2021, 41, 1817-1828.	3.3	2
229	Recent advances in understanding of various chronic pain mechanisms through lysophosphatidic acid (LPA) receptor signaling. Arthritis Research and Therapy, 2012, 14, .	3.5	1
230	Hexapeptide derived from prothymosin alpha attenuates cisplatin-induced acute kidney injury. Clinical and Experimental Nephrology, 2020, 24, 411-419.	1.6	1
231	Âμ-Opioid Receptor. , 1990, , 115-129.		1
232	Identification of novel chemical compounds targeting filovirus VP40-mediated particle production. Antiviral Research, 2022, 199, 105267.	4.1	1
233	Lysophosphatidic acid receptor typeâ€1 mediates brain activation in microâ€positron emission tomography analysis in a fibromyalgiaâ€like mouse model. European Journal of Neuroscience, 2022, 56, 4224-4233.	2.6	1
234	Cellular Mechanisms Underlying Morphine Analgesic Tolerance and Hyperalgesia. , 2009, , 9-20.		0

#	Article	IF	Citations
235	Intermittent cold stress-induced experimental fibromyalgia model in mice - pharmacology and neurobiology. Arthritis Research and Therapy, 2012, 14, .	3.5	0
236	Pilocarpine suppresses hyperalgesia induced by intermittent cold stress (ICS) as an experimental fibromyalgia model in mice. Arthritis Research and Therapy, 2012, 14, .	3.5	0
237	Resistance to morphine analgesia and its underlying mechanisms in an experimental mouse model of fibromyalgia. Arthritis Research and Therapy, 2012, 14, .	3.5	0
238	Energetics and protomer communication in the dynamical structure of S100A13 in free and protein-bound states. Molecular Simulation, 2016, 42, 874-881.	2.0	0
239	Reconstitution of opioid receptor and GTP-binding protein.. Seibutsu Butsuri, 1989, 29, 346-350.	0.1	0
240	Lipid Mediator LPA-Induced Demyelination and Self-Amplification of LPA Biosynthesis in Chronic Pain Memory Mechanisms. , 2015, , 223-236.		0
241	LPA receptor signaling plays a definitive role in pain memory mechanisms in mouse models for neuropathic pain and fibromyalgia. Pain Research, 2017, 32, 239-245.	0.1	0
242	Further in vitro and in vivo studies of newly discovered LPA2 agonists against radiation-induced damages. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-4-9.	0.0	0
243	Brain opioid-mediated analgesia by systemic administration of dipeptide kyotorphin analog. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-2-22.	0.0	0
244	Drug discovery screening based on epigenetic control of COPD â€“ Benserazide inhibits the prothymosin Î±-H1 histone interaction. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2020, 93, 2-LBS-31.	0.0	0